유럽 연합 - 독일어 - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

오스트리아 - 독일어 - AGES (Agentur für Gesundheit und Ernährungssicherheit)

merial s.a.s. - coronavirus; escherichia coli; rotavirus -

유럽 연합 - 독일어 - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immunseren und immunglobuline, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

독일 - 독일어 - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

boehringer ingelheim vetmedica gmbh (3136680) - infektiöses bronchitisvirus, stamm cr88121, lebend - spray zur oralen anwendung, suspension - infektiöses bronchitisvirus, stamm cr88121, lebend (35105) 0,6021 embryo-infektiöse-dosis 50% - huhn

독일 - 독일어 - myHealthbox

hotgen -

오스트리아 - 독일어 - AGES (Agentur für Gesundheit und Ernährungssicherheit)

boehringer ingelheim vetmedica gmbh - infektiÖses bronchitis virus, aviÄr, typ 793/b, stamm cr88121, lebend -

독일 - 독일어 - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

tad pharma gmbh (3044021) - dexamethasondihydrogenphosphat-dinatrium (ph.eur.) - injektionslösung - teil 1 - injektionslösung; dexamethasondihydrogenphosphat-dinatrium (ph.eur.) (02114) 4,372 milligramm

오스트리아 - 독일어 - AGES (Agentur für Gesundheit und Ernährungssicherheit)

hcs b.v. - dexamethason -

오스트리아 - 독일어 - AGES (Agentur für Gesundheit und Ernährungssicherheit)

hcs b.v. - dexamethason -

유럽 연합 - 독일어 - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - impfstoffe - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. der einsatz dieses impfstoffs sollte in übereinstimmung mit den offiziellen empfehlungen.